Consent Under Siege: Parkinson's Patients and the Price of Progress

Imagine losing the ability to walk, speak, or even think clearly, not because your disease progressed, but because you agreed to join a clinical trial. For many late-stage Parkinson's disease (PD) patients, this is a devastating reality. PD is a neurodegenerative disorder that permanently impairs motor function, cognition, and quality of life due to the loss of dopamine-producing neurons [1]. Roughly 81% of patients rely on dopamine-enhancing medications to manage symptoms [2]. In the quest for new solutions, clinical trials require patients to temporarily stop their dopaminergic medications. These trials allow researchers to measure baseline motor function and isolate treatment effects. [3]. While this helps researchers, it comes at a cost.

Withdrawal from these medications in late-stage PD can drastically worsen motor symptoms, cause confusion, emotional instability, and severely compromise decision-making ability [4]. Yet many patients consent without grasping these risks. Cognitive impairment clouds their judgment, while researchers often downplay or fail to communicate the full consequences of withdrawal [5][6]. This disconnect presents neuroethical dilemmas, threatening patients' autonomy, well-being, and dignity. When patients endure unanticipated harm, fundamental ethical principles are violated.

The Consent Crisis

Cognitive decline in Parkinson's is widespread and severe. Around 78% of patients develop dementia within eight years, three times the rate of individuals without PD [6][7]. Even in earlier stages, many experience deficits in memory, executive function, and judgment, with only 15% remaining cognitively intact after 15 years [6]. These impairments undermine late-stage patients' ability to understand risks, calling into question the validity of their consent in clinical trials [8]. Late-stage PD patients are uniquely vulnerable in decisions involving pain, sacrifice, and medical interventions.



Figure 1. Progressive cell loss and neurodegeneration in Parkinson's disease across cognitive stages. Damage to dopaminergic, noradrenergic, and cholinergic systems increases with disease severity, contributing to cognitive decline and loss of autonomy [10].

Given this, is it ethically justifiable to offer cognitively

impaired late-stage PD patients the choice to withdraw the medications that sustain their function? Withdrawal can induce hallucinations, psychosis, and other symptoms that further erode already fragile decision-making capacity [9]. Moreover, the ethical landscape gets murkier on the global stage. Informed consent is not a universal language; some cultures emphasize family decision-making over individual, and many countries lack strong legal protections for vulnerable patients [10]. Even the emphasis and comprehension on risks and safety harms are prone to this variation. In cross-national studies, understanding of clinical trial risks ranged from as low as 7% in some developing regions to 96.6% in others, highlighting disparities in informed understanding [5][11]. This variation complicates ethical clinical trial recruitment and increases risks of exploitation in under regulated regions. In the case of cognitively impaired Parkinson's patients only 17% meet criteria for valid informed consent in drug trials [12]. If patients cannot understand the risks of drug withdrawal, including painful dyskinesia and psychological distress, are their signatures genuine or mere formalities?

The Belmont Report stresses respect for persons, especially those with diminished autonomy and incapacity, implying that such individuals warrant exemption from high-risk activities [13]. Are researchers honoring that mandate when they recruit vulnerable patients for high-risk trials? Or are researchers prioritizing convenience over patient welfare, framing it as progress? When innovation overrides protection, those least able to safeguard themselves are left exposed.

The Dangerous Effects

Withdrawal from dopaminergic medications in PD provokes a dangerous syndrome of psychiatric symptoms, depression, anxiety with panic attacks, agitation, and dysphoria, combined with debilitating motor and autonomic symptoms like severe pain [4]. Abrupt or tapered cessation of levodopa, dopamine agonists, or amantadine can trigger life-threatening withdrawal syndromes [14]. Alarmingly, the research community lacks clear, standardized protocols for safely withdrawing these medications, raising the stakes for the most vulnerable patients [14].

These effects do not merely worsen symptoms; they can shatter a patient's sense of self. [15] The person who consented to research might no longer exists during withdrawal, raising urgent questions about ongoing autonomy and consent. How can continued participation be ethically justified if the patient's identity and decision-making capacity are so profoundly compromised? This problem strikes at the core of ethical research practice in vulnerable populations.

Consider the case of a 75-year-old late-stage PD patient on rasagiline who discontinued the drug due to suspected allergies. Within ten days, she developed severe depression, anxiety, agitation, and aggression, behaviors entirely uncharacteristic of herself. Even after levodopa was resumed, her psychiatric state remained fractured for six months, leaving her cognitively and emotionally altered and incapable of functioning daily [4]. Dopaminergic withdrawal can

dismantle personality, destabilize cognition, and strip patients of the autonomy required for valid informed consent. It raises urgent ethical concerns about enrolling individuals in trials that risk eroding the neurological basis of selfhood.

Future Considerations

The scientific value of dopaminergic withdrawal studies is undeniable; they have advanced our understanding of PD pathophysiology and informed treatment protocols. However, this progress cannot come at the expense of patient autonomy and dignity. The solution lies not in abandoning these studies, but in revolutionizing how we conduct them.

Some researchers argue these trials are essential to understanding PD progression and refining treatments. They may cite safeguards like caregiver consent and monitoring. Such trials have produced useful data on dopamine dependence and symptom expression. However, when a patient's cognition declines, autonomy should not be carelessly delegated or externally substituted. Researchers should consider preparing for trials in advance and going through implications and risks during early stages of PD where cognition is intact. Boards should consider enforcing cognitive screening, continuous consent evaluation, and protocols for crises. Recruitment policies must favor patients over convenience or data expediency.

True progress in Parkinson's research will come from protecting our most vulnerable participants while pursuing the breakthroughs they desperately need. When a clinical trial erases the very individual who consented to participate, no scientific advancement justifies the cost. Protecting the vulnerable is not optional, it is the foundation of responsible research.

References

[1] National Institute of Neurological Disorders and Stroke. Parkinson's disease. Bethesda (MD): National Institute of Neurological Disorders and Stroke; 2025 Mar 5 [cited 2025 Jul 24]. Available from: https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease

[2] Dahodwala N, Willis AW, Li P, Doshi JA. Prevalence and correlates of anti-Parkinson drug use in a nationally representative sample. Mov Disord Clin Pract. 2016 Aug 22;4(3):335–41. doi:10.1002/mdc3.12422. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6174430

[3] National Institutes of Health. Why should I participate in a clinical trial? [Internet]. NIH; 2025 Apr 15 [cited 2025 Jul 25]. Available from: https://www.nih.gov/health-information/nih-clinical-research-trials-you/why-should-i-participate-clinical-trial

[4] Solla P, Ercoli T, Masala C, Orofino G, Fadda L, Corda DG, et al. Rasagiline Withdrawal Syndrome in Parkinson's Disease. Brain Sci. 2022 Feb 5;12(2):219. doi:10.3390/brainsci12020219. Available from: https://www.mdpi.com/2076-3425/12/2/219

[5] Pietrzykowski T, Smilowska K. The reality of informed consent: empirical studies on patient comprehension—systematic review. Trials. 2021 Jan 14;22(1):57. doi:10.1186/s13063-020-04969-w. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7807905

[6] Fang C, Lv L, Mao S, Dong H, Liu B. Cognition deficits in Parkinson's disease: mechanisms and treatment. Parkinsons Dis. 2020 Mar 24;2020:2076942. doi:10.1155/2020/2076942. Available from: https://onlinelibrary.wiley.com/doi/10.1155/2020/2076942

[7] Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8 year prospective study. Arch Neurol. 2003 Mar;60(3):387–92. doi:10.1001/archneur.60.3.387. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/783882

[8] Martin RC, Banks S, Lim S, Miller D, Marson DC. Medical decision making capacity in cognitively impaired Parkinson's disease patients without dementia. Neurology. 2008 Sep 2;71(9):S42–S48. doi:10.1212/01.wnl.0000318208.34321.ad. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579319

[9] Rabinak CA, Nirenberg MJ, Factor SA. Dopamine agonist withdrawal syndrome in Parkinson disease. JAMA Neurol. 2010 Apr;67(4):437–43. doi:10.1001/archneurol.2010.16. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/799048

[10] World Medical Association. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects [Internet]. Ferney-Voltaire: World Medical Association; 2013 [cited 2025 Jul 25]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki

[11] Krosin MT, Acevedo EC, Saksena J. Problems in comprehension of informed consent in rural Mali, West Africa. Int J Health Care Qual Assur. 2006;19(4):339–45. doi:10.1191/1740774506CN150OA. Available from: https://journals.sagepub.com/doi/abs/10.1191/1740774506cn150oa

[12] Karlawish J, Cary M, Moelter ST, Siderowf A, Sullo E, Xie S, et al. Cognitive impairment and PD patients' capacity to consent to research. Neurology. 2013 Aug 27;81(9):801 7. doi:10.1212/WNL.0b013e3182a05ba5. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3908465

[13] National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report: ethical principles and guidelines for the protection of human subjects of research. Washington (DC): U.S. Government Printing Office; 1979 Apr 18. Available from: https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/read-the-belmont-report/index.html

[14] Koschel J, Chaudhuri KR, Tönges L, Thiel M, Raeder V, Jost WH. Implications of dopaminergic medication withdrawal in Parkinson’s disease. J Neural Transm. 2022;129(9):1169–78. doi:10.1007/s00702-021-02389-x. Available from: https://link.springer.com/article/10.1007/s00702-021-02389-x